Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
Efficacy and safety of the Dermatological Soap with ozonated sunflower oil (AGO) and Anti-inflammatory Alcohol Cream in patients with chronic Dermatitis.
View current
Revisiones
List all revisions
Ver
Compare to current
15 Abril 2024 - 1:36pm
por Gladys
19 Diciembre 2025 - 2:18pm
por Gladys
Cambios a
Record Verification Date
-
2024
/
04
/
15
+
2025
/
12
/
19
Cambios a
Next update date
-
2025
/
04
/
15
+
2026
/
12
/
19
Revisión de 19 Diciembre 2025 - 2:18pm
Efficacy and safety of the Dermatological Soap with ozonated sunflower oil (AGO) and Anti-inflammatory Alcohol Cream in patients with chronic Dermatitis.
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Acronym of Public Title:
CREAM-CD
Scientific title:
Evaluation of the efficacy and safety of Dermatological Soap with ozonated sunflower oil (AGO) and Anti-inflammatory Alcohol Cream in patients with chronic Dermatitis.
Acronym of Scientific Title:
Cream - Chronic Dermatitis
Secondary indentifying numbers:
CREMA-DC-01
Issuing authority of the secondary identifying numbers:
National Center for Scientific Research
Primary sponsor:
National Center for Scientific Research
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Ministry of Science, Technology and Enviroment (CITMA)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Mayilenis
Last name:
Gondres Mora
Medical Specialty :
First Degree Specialist in Dermatology
Affiliation:
10 de Octubre Clinical Surgical Teaching Hospital
Postal address:
10 de Otubre No 130/ Agua Dulce y Serafines, Cerro
City:
Havana
País:
Cuba
Zip Code:
10300
Telephone:
+53-54804696
Email address:
mayilenis@infomed.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Havana, "General Peraza" Elderly House, Mayilenis Gondres Mora, MD. First Degree Specialist in Dermatology
Havana, "28 de Enero" Elderly House, Mayilenis Gondres Mora, MD. First Degree Specialist in Dermatology
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
02/09/2024
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Chronic dermatitis
Intervention(s):
Group 1 (Experimental): Dermatological soap with AGO. The soap will use for bathing and cleaning the affected areas during 8 weeks. Group 2 (Control): Anti-inflammatory alcohol cream. The cream should be applied in a thin layer to the affected areas twice a day, preferably in the morning and at night after washing the lesions with the products you usually use the cream will use for 8 weeks. Group 3 (Experimental): Dermatological soap with AGO - anti-inflammatory alcohol cream. The soap will use for bathing and cleaning the affected areas. The cream should be applied in a thin layer to the affected areas twice a day, preferably in the morning and evening, after washing the lesions with the dermatological soap. The soap and the cream will use for 8 weeks.
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
1. Cure clinical (elimination of itching and absence of lesions typical of chronic dermatitis. or clinical improvement and mycological negativization) or Clinical improvement (Reduction in pruritus and improvement in lesions). Measurement time: At baseline and, Week 2, 4, 6 and 8 of treatment 2. Mycological cure (negative mycological examination). Measurement time: At baseline and, Week 8 of treatment
Key secondary outcomes:
1. EASI Scale (Eczema Area and Severity Index). Measurement time: At baseline and, Week 2, 4, 6 and 8 of treatment 2. VAS Scale (Visual Analogue Scale adapted to Pruritus). Measurement time: At baseline and, Week 2, 4, 6 and 8 of treatment 3. Life Quality Index Score of patients with Chronic Dermatitis (DLQI). Measurement time: At baseline and, Week 2, 4, 6 and 8 of treatment
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
19 years
Maximum age:
None
Inclusion criteria:
Patients with 19 years old or older, of both sexes, who have signed their informed consent to participate in the study, with a clinical diagnosis of chronic dermatitis, treatment-naïve or with more than five days without specific topical or systemic treatment.
Exclusion criteria:
1. Decompensated diabetes mellitus (fasting glucose > 7 mmol/L). 2. Skin neoplasms diagnosed in the area to be treated. 3. Associated septic states that require immediate treatment. 4. History of liver disease or chronic kidney disease. 5. Other decompensated chronic diseases. 6. Pregnancy. 7. Concomitant use of corticosteroids, cytostatics or immunosuppressants and antibiotics. 8. Moderate-severe cognitive disorders. 9. Usual medical history of allergy to medications or any other special condition that, in the doctor's opinion, puts your health and life at risk during the study.
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Treatment
Allocation:
Randomized controlled trial
Masking:
Open
Control group:
Active
Study design:
Parallel
Phase:
N/A
Target sample size:
90
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Mayilenis
Last Name:
Gondres Mora
Specialty:
First Degree Specialist in Dermatology
Affiliation:
10 de Octubre Clinical Surgical Teaching Hospital
Postal Address:
10 de Octubre No 130 /Agua Dulce y Serafines, Cerro
City:
Havana
País:
Cuba
Zip Code:
10300
Telephone:
+53-54804696
Email :
mayilenis@infomed.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Julio
Middle Name:
Cesar
Last Name:
Fernandez Travieso
Specialty:
Doctor in Pharmaceutical Sciences
Affiliation:
National Center for Scientific Research
Postal Address:
25 Avenue and 158 Street, Cubanacan, Playa
City:
Havana
País:
Cuba
Zip Code:
11300
Telephone:
+53-59958136
Email :
julio.fernandez@cnic.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
10 de Octubre Clinical Surgical Teaching Hospital
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
30/11/2023
Postal address of Ethic Committee :
10 de Octubre No. 130 e/ Agua Dulce y Serafines. Cerro, ZC:10300, La Habana. Cuba
Telephone:
+53-78252292
Correo electrónico:
manuel.hernandez@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
27/01/2025
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000437
Date of Registration in Primary Registry:
15/04/2024
Record Verification Date:
2025/12/19
Next update date:
2026/12/19
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos